<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710866</url>
  </required_header>
  <id_info>
    <org_study_id>PHAC 6273-15-2008/4160872</org_study_id>
    <nct_id>NCT00710866</nct_id>
  </id_info>
  <brief_title>Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity</brief_title>
  <acronym>TITRE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Centre for Disease Control</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Centre for Disease Control</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the antibody response and reaction rates in children
      age 6-23 months when they are given either the currently recommended schedule of two 0.25ml
      doses of influenza vaccine one month apart or two 0.5ml doses of influenza vaccine, one month
      apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
    <description>Seroprotection rate: HI titers =&gt;40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/59/07(H1N1)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
    <description>Seroprotection rate: HI titers =&gt;40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate Infants(6-11 Months)-A/Brisbane/10/07(H3N2)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
    <description>Seroprotection rate: HI titers =&gt;40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/10/07(H3N2)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
    <description>Seroprotection rate: HI titers =&gt;40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate Infants (6-11 Months)-B/Florida/4/06(Yamagata)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate Toddlers (12-23 Months)-B/Florida/4/06(Yamagata)</measure>
    <time_frame>27-46 days after the second dose</time_frame>
    <description>Seroprotection rate: HI titers =&gt;40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events: Fever After Either Dose - Infants 6-11 Months</measure>
    <time_frame>3 days after immunization</time_frame>
    <description>Fever defined as temperature &gt;= 38 C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events: Fever After Either Dose - Toddlers(12-23 Months)-</measure>
    <time_frame>3 days after immunization</time_frame>
    <description>Fever defined as temperature &gt;= 38 C</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)</intervention_name>
    <description>Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>VAXIGRIP®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child healthy (stable chronic conditions acceptable) as established by health
             assessment interview and verbal history-directed health examination

          -  Child between and including 6 months of age and 23 months of age (up to and including
             the day before 24 months of age)

          -  Child is available and can complete all relevant procedures during the entire study
             period

          -  Parent or legal guardian is available and can be reached by phone during the entire
             study period

          -  Parent/guardian provides written informed consent

          -  Parent/guardian is fluent in English

        Exclusion Criteria:

          -  Child has history of laboratory-confirmed influenza

          -  Child has history of any prior influenza immunization

          -  Child has history of anaphylactic reaction to any component of the vaccine (i.e. egg)

          -  Child has received immune globulin or other blood products within the prior six weeks

          -  Child has received injected or oral steroids within the prior six weeks (inhaled or
             topical steroids allowed)

          -  Child has a bleeding diathesis or condition associated with prolonged bleeding time
             that would contraindicate intramuscular injection (thrombocytopenia, coagulation
             disorder, anti-coagulant therapy)

          -  Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical
             device during the study period

          -  Child is scheduled to receive a live vaccine (notably measles, mumps, rubella or
             varicella vaccines) during the study period

          -  Child has a health condition which, in the opinion of the investigator, would
             interfere with the evaluation or pose a health risk to the child
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danuta M Skowronski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Centre for Disease Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3C 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University / IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Vaccine Study Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université de Laval - Unité de recherche en santé publique</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <results_first_submitted>July 11, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Danuta M. Skowronski</name_title>
    <organization>BC Centre for Disease Control</organization>
  </responsible_party>
  <keyword>Influenza Vaccines</keyword>
  <keyword>Infant</keyword>
  <keyword>Dose-Response Relationship, Immunologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.5mL VAXIGRIP®</title>
          <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
        </group>
        <group group_id="P2">
          <title>0.25mL VAXIGRIP®</title>
          <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5mL VAXIGRIP®</title>
          <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
        </group>
        <group group_id="B2">
          <title>0.25mL VAXIGRIP®</title>
          <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.4"/>
                    <measurement group_id="B2" value="1.1" spread="0.4"/>
                    <measurement group_id="B3" value="1.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1)</title>
        <description>Seroprotection rate: HI titers =&gt;40</description>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1)</title>
          <description>Seroprotection rate: HI titers =&gt;40</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="9.8" upper_limit="15.2"/>
                    <measurement group_id="O2" value="34" lower_limit="8.2" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/59/07(H1N1)</title>
        <description>Seroprotection rate: HI titers =&gt;40</description>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/59/07(H1N1)</title>
          <description>Seroprotection rate: HI titers =&gt;40</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Infants(6-11 Months)-A/Brisbane/10/07(H3N2)</title>
        <description>Seroprotection rate: HI titers =&gt;40</description>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Infants(6-11 Months)-A/Brisbane/10/07(H3N2)</title>
          <description>Seroprotection rate: HI titers =&gt;40</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/10/07(H3N2)</title>
        <description>Seroprotection rate: HI titers =&gt;40</description>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/10/07(H3N2)</title>
          <description>Seroprotection rate: HI titers =&gt;40</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="10.9" upper_limit="15.7"/>
                    <measurement group_id="O2" value="52" lower_limit="7.5" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Infants (6-11 Months)-B/Florida/4/06(Yamagata)</title>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Infants (6-11 Months)-B/Florida/4/06(Yamagata)</title>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="10.8" upper_limit="17.1"/>
                    <measurement group_id="O2" value="26" lower_limit="6.7" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Toddlers (12-23 Months)-B/Florida/4/06(Yamagata)</title>
        <description>Seroprotection rate: HI titers =&gt;40</description>
        <time_frame>27-46 days after the second dose</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Toddlers (12-23 Months)-B/Florida/4/06(Yamagata)</title>
          <description>Seroprotection rate: HI titers =&gt;40</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events: Fever After Either Dose - Infants 6-11 Months</title>
        <description>Fever defined as temperature &gt;= 38 C</description>
        <time_frame>3 days after immunization</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events: Fever After Either Dose - Infants 6-11 Months</title>
          <description>Fever defined as temperature &gt;= 38 C</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events: Fever After Either Dose - Toddlers(12-23 Months)-</title>
        <description>Fever defined as temperature &gt;= 38 C</description>
        <time_frame>3 days after immunization</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mL VAXIGRIP®</title>
            <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
          </group>
          <group group_id="O2">
            <title>0.25mL VAXIGRIP®</title>
            <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events: Fever After Either Dose - Toddlers(12-23 Months)-</title>
          <description>Fever defined as temperature &gt;= 38 C</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited adverse events were recorded using memory aid after immunization for days 0 to 7 after each injection; reports shown for days 0 to 3 after either injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.5mL VAXIGRIP®</title>
          <description>2 doses 0.5mL VAXIGRIP® at months 0, 1</description>
        </group>
        <group group_id="E2">
          <title>0.25mL VAXIGRIP®</title>
          <description>2 doses 0.25mL VAXIGRIP® at months 0, 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="124"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="74" subjects_affected="74" subjects_at_risk="124"/>
                <counts group_id="E2" events="77" subjects_affected="77" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="124"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="124"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="124"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Teething</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="124"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="124"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="124"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="124"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Danuta M Skowronski, MD</name_or_title>
      <organization>British Columbia Centre for Disease Control</organization>
      <phone>604-660-6067</phone>
      <email>danuta.skowronski@bccdc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

